Arcellx Inc Market Cap ($6.73 Billion)
Market Cap & Net Worth: Arcellx Inc (ACLX)
Arcellx Inc market cap. Arcellx Inc (NASDAQ:ACLX) has a market capitalization of $6.73 Billion ($6.73 Billion) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2849 globally and #1048 in its home market, demonstrating a 0.06% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Arcellx Inc's stock price $115.07 by its total outstanding shares 58506348 (58.51 Million). Also see Arcellx Inc operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Arcellx Inc Market Cap History (2022–2026)
Arcellx Inc market cap history from 2022 to 2026. Data shows growth from $1.81 Billion to $6.73 Billion (56.82% CAGR). Check today's stock price for Arcellx Inc for real-time trading data and today's change.
Index Memberships
Arcellx Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.26% | #71 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.02% | #326 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.37% | #49 of 263 |
Weight: Arcellx Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Arcellx Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Arcellx Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Arcellx Inc growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
171.17x
Arcellx Inc's market cap is 171.17 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $1.81 Billion | $17.91 Million | -$188.68 Million | 101.19x | N/A |
| 2023 | $3.25 Billion | $110.32 Million | -$70.69 Million | 29.43x | N/A |
| 2024 | $4.49 Billion | $107.94 Million | -$107.35 Million | 41.57x | N/A |
| 2025 | $3.81 Billion | $22.29 Million | -$228.93 Million | 171.17x | N/A |
Competitor Companies of ACLX by Market Capitalization
Companies near Arcellx Inc in the global market cap rankings as of November 1, 2026. Also see balance sheet size of Arcellx Inc for a full breakdown of the balance sheet.
Key companies related to Arcellx Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Arcellx Inc (2022–2026)
Market capitalization of Arcellx Inc from 2022 to today. Between 2022 and today, Arcellx Inc's market cap moved from $1.81 Billion to $ 6.73 Billion, with a yearly change of 56.82%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $6.73 Billion | +76.49% |
| 2025 | $3.81 Billion | -14.98% |
| 2024 | $4.49 Billion | +38.18% |
| 2023 | $3.25 Billion | +79.15% |
| 2022 | $1.81 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Arcellx Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.73 Billion USD |
| MoneyControl | $6.73 Billion USD |
| MarketWatch | $6.73 Billion USD |
| marketcap.company | $6.73 Billion USD |
| Reuters | $6.73 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Arcellx Inc
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a prod… Read more